Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 26 of 26 publications.
Skip to main content
Belozeroff V, Chertow GM, Graham CN, Dehmel D, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007
Yaylali E, Farnham PG, Hicks KA, Honeycutt A, Sansom SL, Tucker EL. Developing a dynamic compartmental model of HIV in the United States. Poster presented at the INFORMS Annual Meeting; November 3, 2015. Philadelphia, PA.
Graham CN, McBride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Graham C, Knox H, Hess LM, Jen M, Cuyun Carter G, Chandrawansa K, Boye M. Cost-effectiveness in the second-line treatment of non-small cell lung cancer (NSCLC) in the US. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp M, Griffiths M, Agirrezabal I, Brennan A. Cost-utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria (CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Partha G, Gupta S, Bhattacharyya S, Halliday A, McBride D, Graham J, Balp MM, Marsland A. Adapting literature-based remission rates for chronic spontaneous/idiopathic urticaria to the needs of a health economic model: a Kaplan-Meier approach. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Chen YH, Yaylali E, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Calibrating dynamic compartmental models of human immunodeficiency virus in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 37th Annual North American Meeting; October 18, 2015. St. Louis, MO.
Hicks KA, Bowers LD. A model for developing athlete testing strategies based on the costs and benefits of doping. Presented at the 14th Annual USADA Symposium on Anti-Doping Science; October 4, 2015. Leesburg, VA.
Talbird SE, Brogan AJ, La EH, Perard R. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in France and Spain. Poster presented at the Health Technology Assessment international; June 14, 2015. Oslo, Norway.
Wilson MR, Mody R, Ursan I, Carr SM. Cost-effectiveness of vedolizumab compared with conventional therapy and biologics for treatment of moderately to severely active ulcerative colitis in the United States. Poster presented at the 2015 Digestive Disease Week; May 16, 2015. San Diego, CA.
Mauskopf JA, Graham J, Fay-Azhar M, Kinter E. Budget impact of adding peginterferon beta-1a to the formulary for the treatment of relapsing forms of multiple sclerosis. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Graham CN, Mollon P, Miles L, McBride D. A new cost-effectiveness framework for modeling psoriasis treatment. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Wilson M, Mody R, Ursan I, Carr S. The budgetary impact of vedolizumab in the management of moderately to severely active ulcerative colitis and Crohn's disease in the United States. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S57.
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Herring WL, Grant TJ, Mladsi DM. A mathematical model to estimate the health benefits and costs of diabetic retinopathy screening programs. Presented at the 2015 Institute for Operations Research and Management Science Computing Conference; January 12, 2015. Richmond, VA.
Beard SM, Gaffney L, Bamber L. Economic modelling of antiplatelet therapy in the secondary prevention of stroke. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 9, 2003. Barcelona, Spain.
von Scheele B, DePlatchett J, Gaffney L, Peña BM, Niculescu L. The total costs of treatment with valdecoxib compared to generic diclofenac are similar in patients with rheumatoid arthritis in Germany. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 9, 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):725-6.
Sorensen SW, Hicks KA, Wirth K, Hoerger TJ, Narayan K, Saaddine J. Optimal allocation of resources based on the diabetes report card for quality care. Presented at the Institute for Operations Research and the Management Sciences Annual Meeting; October 2003.
Neighbors DM, McCory D, Pesa J. Cost-effectiveness and budget impact of zolmitriptan nasal spray. Poster presented at the 2003 AMCP Educational Conference; October 2003. Montreal, Canada.
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D, Mobley LR. Benefits and costs of methadone treatment: results from a lifetime simulation model. Presented at the International Health Economics Association Meeting; June 15, 2003.
Fehnel SE, McLeod LD, Williams VS. Combining qualitative and quantitative techniques in the development of patient-reported outcome measures. Presented at the Eighth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 2003.
Hicks KA, Honeycutt A, Earnshaw SR, Richter A. Models for the efficient allocation of HIV prevention resources. Presented at the Community Planning Leadership Summit for HIV Prevention; March 2003.
Beard S, Gaffney L, Bamber L. Economic modelling of antiplatelet therapy in the prevention of recurrent stroke. Value Health. 2003 Jan 1;6(6):650.